PriceTargets.com logo

Salarius Pharmaceuticals - SLRX Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$1.66 As of 12/26/2024 06:45 PM ET
▲ +0.1735 (11.64%)

This chart shows the closing price for SLRX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Salarius Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SLRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SLRX

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Salarius Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $1.66.

This chart shows the closing price for SLRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Salarius Pharmaceuticals. This rating has held steady since July 2024, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/5/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/3/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/1/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/31/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/11/2023LADENBURG THALM/SH SHDowngradeBuy ➝ Neutral
3/11/2022HC WainwrightLower TargetBuy$1,000.00 ➝ $800.00
8/25/2021HC WainwrightInitiated CoverageBuy$1,000.00
6/16/2020BenchmarkInitiated CoverageBuy$1,000.00
4/27/2020LADENBURG THALM/SH SHInitiated CoverageBuy
(Data available from 12/26/2019 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/30/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/29/2024
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/29/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/28/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/27/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/27/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/26/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/26/2024

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Salarius Pharmaceuticals logo
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. The company is headquartered in Houston, Texas.
Read More

Today's Range

Now: $1.66
Low: $1.42
High: $1.72

50 Day Range

MA: $1.52
Low: $1.22
High: $2.01

52 Week Range

Now: $1.66
Low: $1.22
High: $7.20

Volume

94,123 shs

Average Volume

706,513 shs

Market Capitalization

$2.40 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.92

Frequently Asked Questions

What sell-side analysts currently cover shares of Salarius Pharmaceuticals?

The following Wall Street analysts have issued reports on Salarius Pharmaceuticals in the last year:
View the latest analyst ratings for SLRX.

What is the current price target for Salarius Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Salarius Pharmaceuticals in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Salarius Pharmaceuticals in the next year.
View the latest price targets for SLRX.

What is the current consensus analyst rating for Salarius Pharmaceuticals?

Salarius Pharmaceuticals currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for SLRX.

What other companies compete with Salarius Pharmaceuticals?

Other companies that are similar to Salarius Pharmaceuticals include Indaptus Therapeutics, Aytu BioPharma, Cyclerion Therapeutics, Addex Therapeutics and Orgenesis. Learn More about companies similar to Salarius Pharmaceuticals.

How do I contact Salarius Pharmaceuticals' investor relations team?

Salarius Pharmaceuticals' physical mailing address is 2450 Holcombe Blvd. Suite X, Houston TX, 77021. The company's listed phone number is (832) 834-6992 and its investor relations email address is [email protected]. The official website for Salarius Pharmaceuticals is www.salariuspharma.com. Learn More about contacing Salarius Pharmaceuticals investor relations.